vilobelimab (Gohibic)
Jump to navigation
Jump to search
Indications
- hospitalized patients with severe COVID-19 within 48 hours of starting mechanical ventilation or extracorporeal membrane oxygenation
* FDA-approved for Emergency Use Authorization
Mechanism of action
- anti-C5a monoclonal antibody that targets an inflammatory pathway believed to be involved in COVID-19 progression
More general terms
References
- ↑ Harris E FDA Approves Vilobelimab for Emergency Use in Hospitalized Adults. JAMA. Published online April 19, 2023. https://jamanetwork.com/journals/jama/fullarticle/2804233